Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.

摘要: Abstract Aims. Gastric cancer in Western countries is often diagnosed an advanced stage and prognosis poor. We performed a randomised trial with pre-operative FAMTX vs. surgery alone order to evaluate the effect of chemotherapy on resectability survival. Methods. Patients proven adenocarcinoma stomach were receive four courses using 5-Fluorouracil, doxorubicin methotrexate (FAMTX) prior or undergo alone. Results. Fifty-nine patients randomised; 29 allocated regimen 30 had Resectability rates equal for both groups. Complete partial response was registered 32% group. With median follow-up 83 months survival since randomisation 18 group ( p =0.17). Conclusions . This could not show beneficial FAMTX. Until large studies prove otherwise, adequate without delay best treatment operable gastric cancer.